Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-03-2016 | Original Article

Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome

Authors: Sachin Punatar, Alok Gupta, Jayant Gawande, Bhausaheb Bagal, Libin Mathew, Sadhana Kannan, Navin Khattry

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 1/2016

Login to get access

Abstract

Chronic graft versus host disease (cGVHD) is a common late complication of allogenic hematopoietic stem cell transplant (HSCT). We analyzed risk factors, pattern and long term transplant outcomes of cGVHD at a tertiary cancer centre. Seventy-seven consecutive patients who underwent HSCT for acute leukemia were included. Forty (52 %) patients developed cGVHD; 24 (60 %) extensive stage while 16 (40 %) limited stage. Oral cavity was the commonest site of involvement (25 patients) followed by liver, skin and lung. We found that female donor to male recipient transplant and diagnosis of acute lymphoblastic leukemia (ALL) were the only factors associated with increased risk of cGVHD. The incidence of leukemia relapse was 18 % in patients who developed cGVHD compared to 51 % in those who did not (P = 0.002). Four year overall survival and relapse free survival (RFS) were 62 and 46 % in patients who developed cGVHD compared to 29 % (P < 0.001) and 29 % (P < 0.001) in patients who did not develop cGVHD, respectively. We conclude that cGVHD is more common in male patients with female donors and in patients transplanted for ALL. Oral cavity is the commonest site of cGVHD in our patients and transplant related survival outcomes are superior in patients who develop cGVHD.
Literature
1.
go back to reference Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2008) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl 28:121–129CrossRef Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP (2008) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transpl 28:121–129CrossRef
2.
go back to reference Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100:1192–1200CrossRefPubMed Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al (2002) Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood 100:1192–1200CrossRefPubMed
3.
go back to reference Lee SJ, Vogelsang G, Flowers ME (2003) Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl 9:215–233CrossRef Lee SJ, Vogelsang G, Flowers ME (2003) Chronic Graft-versus-Host Disease. Biol Blood Marrow Transpl 9:215–233CrossRef
4.
go back to reference Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459–2464PubMed Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al (1990) Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459–2464PubMed
5.
go back to reference Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al (2003) Graft-versus-host disease following allogenic transplantation from HLA-identical sibling with anti thymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470–476CrossRefPubMed Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al (2003) Graft-versus-host disease following allogenic transplantation from HLA-identical sibling with anti thymocyte globulin-based reduced-intensity preparative regimen. Blood 102:470–476CrossRefPubMed
6.
go back to reference Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M (2013) Incidence and pattern of graft-versus-host disease in patients undergoing allogenic transplantation after non myeloablative conditioning with total lymphoid irradiation and anti thymocyte globulin. Bone Marrow Res. doi:10.1155/2013/414959 PubMedCentralPubMed Veltri L, Regier M, Cumpston A, Leadmon S, Tse W, Craig M, Hamadani M (2013) Incidence and pattern of graft-versus-host disease in patients undergoing allogenic transplantation after non myeloablative conditioning with total lymphoid irradiation and anti thymocyte globulin. Bone Marrow Res. doi:10.​1155/​2013/​414959 PubMedCentralPubMed
7.
go back to reference Gota V, Pathak K, Mittal S et al (2014) A limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil for prophylaxis of acute graft versus host disease in allogeneic stem cell transplantation. Bone Marrow Transpl 49:S295 Gota V, Pathak K, Mittal S et al (2014) A limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil for prophylaxis of acute graft versus host disease in allogeneic stem cell transplantation. Bone Marrow Transpl 49:S295
8.
go back to reference Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217CrossRefPubMed Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al (1980) Chronic graft versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69:204–217CrossRefPubMed
9.
go back to reference Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11:945–956CrossRef Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl 11:945–956CrossRef
10.
11.
go back to reference Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N et al (2012) Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transpl 47:1564–1568CrossRef Dhédin N, Prébet T, De Latour RP, Katsahian S, Kuentz M, Piard N et al (2012) Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transpl 47:1564–1568CrossRef
12.
go back to reference Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J et al (2012) Long-term follow up after allogenic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin. Haematologica 97:710–716PubMedCentralCrossRefPubMed Konopacki J, Porcher R, Robin M, Bieri S, Cayuela JM, Larghero J et al (2012) Long-term follow up after allogenic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin. Haematologica 97:710–716PubMedCentralCrossRefPubMed
13.
go back to reference Solano C, Martinez C, Brunet S, Tomás JF, Urbano-Ispizua A, Zuazu J et al (1998) Chronic graft versus host disease after allogenic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study. Bone Marrow Transpl 22:1129–1135CrossRef Solano C, Martinez C, Brunet S, Tomás JF, Urbano-Ispizua A, Zuazu J et al (1998) Chronic graft versus host disease after allogenic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case–control study. Bone Marrow Transpl 22:1129–1135CrossRef
14.
go back to reference Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al (2002) Severity of chronic graft-versus-host disease: association with treatment related mortality and relapse. Blood 100:406414 Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al (2002) Severity of chronic graft-versus-host disease: association with treatment related mortality and relapse. Blood 100:406414
15.
go back to reference Pidala J (2011) Graft-vs-host disease following allogenic hematopoietic cell transplantation. Cancer Control 18:268–276PubMed Pidala J (2011) Graft-vs-host disease following allogenic hematopoietic cell transplantation. Cancer Control 18:268–276PubMed
Metadata
Title
Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome
Authors
Sachin Punatar
Alok Gupta
Jayant Gawande
Bhausaheb Bagal
Libin Mathew
Sadhana Kannan
Navin Khattry
Publication date
01-03-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0506-5

Other articles of this Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine